News

Bristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with Disabilities

Bristol Myers Squibb (NYSE:BMY) today announced, in collaboration with Disability Solutions, a U.S.- based non-profit organization that supports companies globally to achieve true disability inclusion, the launch of the Disability Diversity in Clinical Trials (DDiCT) initiative. This new initiative aligns with Bristol Myers Squibb’s broader inclusion and diversity health equity commitments to address health disparities, clinical trial diversity, supplier diversity, employee giving, and workforce representation between 2020 and 2025.

The DDiCT initiative initially aims to make recommendations on how to effectively improve access, engagement, speed of enrollment, and participation of people with disabilities in clinical trials, to ensure all patient groups are reflective of the real-world population and aligned with the epidemiology of the disease studies. This project was initiated by the Bristol Myers Squibb People & Business Resource Group DAWN (Disability Advancement Workplace Network) and will be co-led by DAWN and the Global Drug Development Team.

“Through this work, Bristol Myers Squibb can set the standard and stage for access to life-changing and life-saving medicines for people with disabilities,” said Samit Hirawat, M.D., executive vice president and chief medical officer, Global Drug Development, Bristol Myers Squibb. “The long-term goal of our DDiCT program is to develop and pilot trials that are accessible to the widest variety of patients.”

Current common clinical trial practices exclude up to one-fourth of the U.S. population-based on disability status. According to a study published in the Journal of the American Medical Association, in 338 phase III and IV studies, 12.4% of people with intellectual or developmental disabilities and 1.8% of those with physical disabilities failed to be included due to explicit exclusion criteria. The study also identified that additional barriers for disability diversity within clinical trials are caused by inaccessible trial sites, medical equipment, and ableist biases which deter this community from receiving potentially life-saving treatments.

“People with disabilities are omitted from conversations about diversity and inclusion, despite being the largest underrepresented group in the world and the only underrepresented group anyone can join at any given moment. Therefore, it’s essential that we broaden the scope of medical trials and research,” said Tinamarie Duff, DAWN Global People & Business Resource Group Lead, Bristol Myers Squibb. “The launch of the DDiCT, especially during Disability Pride Month, supports Bristol Myers Squibb’s overall commitment to address every dimension of diversity, which means making the most effective medicine to include people with disabilities at all stages of access/trials.”

Read more here.

Recent News

03/21/2023

Mason leads planning study to position Northern Virginia as a premier location for the life science industry

During the past several years, industry demand for a skilled life science workforce has been surging. In Virginia, while there are currently shortages in almost all health-related professions, little is known about whether there is an adequate supply of life science workers to meet the needs of employers. Now George Mason University is working toward

03/21/2023

California invests $50M to partner with Civica Rx on insulin manufacturing

California Gov. Gavin Newsom has announced a new contract with nonprofit drugmaker Civica Rx, a move that brings the state one step closer to creating its own line of insulin to bring down the cost of the drug. Once the medicines are approved by the Food and Drug Administration, Newsom said at a press conference

03/07/2023

RAMP Welcomes 5 Startups into Spring 2023 Cohort

From designing battery electric spotter tractors to developing individualized neuro-oncology treatments for aggressive gliomas, the five companies accepted into RAMP’s Spring 2023 Cohort span the gamut of technology, health science and life science innovation. “We are thrilled to welcome these inspiring entrepreneurs and help them accelerate their vision,” said RAMP director Lisa Garcia. “Not only